30 April 2021 - The US FDA on Friday revoked a policy issued in the final days of the Trump administration that was purportedly aimed at increasing transparency related to drug review timelines.

The policy, announced by the Department of Health and Human Services on 15 January 2021, would have required FDA to publish “redundant” information on new drug applications and abbreviated new drug applications submitted to the agency for review.

Read Regulatory Affairs Professional Society article